Pediatric Multiple Sclerosis

Neurologic Clinics

Volumn 29, Issue 2, 2011, Pages 481-505

  Chitnis, Tanuja ^a   Krupp, Lauren ^b   Yeh, Ann ^c   Rubin, Jennifer ^d   Kuntz, Nancy ^d   Strober, Jonathan B ^e   Chabas, Dorothee ^e   Weinstock Guttmann, Bianca ^c   Ness, Jayne ^f   Rodriguez, Moses ^g   Waubant, Emmanuelle ^e  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b STONY BROOK UNIVERSITY   (United States)

^c JACOBS NEUROLOGICAL INSTITUTE   (United States)

^d CHILDREN'S MEMORIAL HOSPITAL   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UAB Center for Pediatric Onset Demyelinating Disease   (United States)

^g MAYO CLINIC   (United States)

Author keywords

Children; Multiple sclerosis; Pediatric; Treatment

Indexed keywords

BETA1A INTERFERON; CYCLOPHOSPHAMIDE; GLATIRAMER; MITOXANTRONE; NATALIZUMAB; RITUXIMAB;

ACUTE DISSEMINATED ENCEPHALOMYELITIS; ACUTE LEUKEMIA; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; BLADDER CARCINOMA; CARDIOMYOPATHY; CHILD; CLINICAL FEATURE; DIAGNOSTIC TEST; DIFFERENTIAL DIAGNOSIS; DISABILITY; DISEASE COURSE; DISEASE PREDISPOSITION; ENVIRONMENTAL FACTOR; FLU LIKE SYNDROME; HUMAN; IMMUNOLOGY; INCIDENCE; INFERTILITY; INJECTION SITE REACTION; LEUKOPENIA; LIVER FUNCTION TEST; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOPOROSIS; PATHOPHYSIOLOGY; PEDIATRICS; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SIDE EFFECT; THORAX PAIN; THROMBOCYTOPENIA;

COGNITION DISORDERS; DIAGNOSIS, DIFFERENTIAL; DISABILITY EVALUATION; DISEASE SUSCEPTIBILITY; FATIGUE; HUMANS; MENTAL DISORDERS; MULTIPLE SCLEROSIS; PEDIATRICS; QUALITY OF LIFE;

EID: 79952854048     PISSN: 07338619     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ncl.2011.01.004     Document Type: Review

References (140)

1. Duquette P., Murray T.J., Pleines J., et al. Multiple sclerosis in childhood: clinical profile in 125 patients. J Pediatr 1987, 111(3):359-363.
2. Poser C.M., Paty D.W., Scheinberg L., et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983, 13(3):227-231.
3. McDonald W.I., Compston A., Edan G., et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol 2001, 50(1):121-127.
4. Polman C.H., Reingold S.C., Edan G., et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the " McDonald Criteria" Ann Neurol 2005, 58(6):840-846.
5. Waubant E., Chabas D. Pediatric multiple sclerosis. Curr Treat Options Neurol 2009, 11(3):203-210.
6. Krupp L.B., Banwell B., Tenembaum S. Consensus definitions proposed for pediatric multiple sclerosis and related disorders. Neurology 2007, 68(16 Suppl 2):S7-S12. International Pediatric MS Study Group.
7. Renoux C., Vukusic S., Mikaeloff Y., et al. Natural history of multiple sclerosis with childhood onset. N Engl J Med 2007, 356(25):2603-2613.
8. Chitnis T., Glanz B., Jaffin S., et al. Demographics of pediatric-onset multiple sclerosis in an MS center population from the Northeastern United States. Mult Scler 2009, 15(5):627-631.
9. Ghezzi A., Deplano V., Faroni J., et al. Multiple sclerosis in childhood: clinical features of 149 cases. Mult Scler 1997, 3(1):43-46.
10. Boiko A., Vorobeychik G., Paty D., et al. Early onset multiple sclerosis: a longitudinal study. Neurology 2002, 59(7):1006-1010.
11. Ferreira M.L., Machado M.I., Dantas M.J., et al. Pediatric multiple sclerosis: analysis of clinical and epidemiological aspects according to National MS Society Consensus 2007. Arq Neuropsiquiatr 2008, 66(3B):665-670.
12. Fromont A., Binquet C., Sauleau E.A., et al. Geographic variations of multiple sclerosis in France. Brain 2010, 133(Pt 7):1889-1899.
13. Klein N.P., Ray P., Carpenter D., et al. Rates of autoimmune diseases in Kaiser Permanente for use in vaccine adverse event safety studies. Vaccine 2010, 28(4):1062-1068.
14. Chong H.T., Li P., Benjamin O.N.G., et al. Pediatric multiple sclerosis is similar to adult-onset form in Asia. Neurology Asia 2007, 12:37-40.
15. Chitnis T. Pediatric multiple sclerosis. Neurologist 2006, 12(6):299-310.
16. Banwell B., Krupp L., Kennedy J., et al. Clinical features and viral serologies in children with multiple sclerosis: a multinational observational study. Lancet Neurol 2007, 6(9):773-781.
17. Kennedy J., O'Connor P., Sadovnick A.D., et al. Age at onset of multiple sclerosis may be influenced by place of residence during childhood rather than ancestry. Neuroepidemiology 2006, 26(3):162-167.
18. McAdam L.C., Blaser S.I., Banwell B.L. Pediatric tumefactive demyelination: case series and review of the literature. Pediatr Neurol 2002, 26(1):18-25.
19. Anderson R.C., Connolly E.S., Komotar R.J., et al. Clinicopathological review: tumefactive demyelination in a 12-year-old girl. Neurosurgery 2005, 56(5):1051-1057. [discussion: 1051-7].
20. Riva D., Chiapparini L., Pollo B., et al. A case of pediatric tumefactive demyelinating lesion misdiagnosed and treated as glioblastoma. J Child Neurol 2008, 23(8):944-947.
21. Dastgir J., DiMario F.J. Acute tumefactive demyelinating lesions in a pediatric patient with known diagnosis of multiple sclerosis: review of the literature and treatment proposal. J Child Neurol 2009, 24(4):431-437.
22. Vanlandingham M., Hanigan W., Vedanarayanan V., et al. An uncommon illness with a rare presentation: neurosurgical management of ADEM with tumefactive demyelination in children. Childs Nerv Syst 2010, 26:655-661.
23. Lucchinetti C., Bruck W., Parisi J., et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000, 47(6):707-717.
24. Chitnis T. The role of CD4 T cells in the pathogenesis of multiple sclerosis. Int Rev Neurobiol 2007, 79:43-72.
25. Banwell B., Bar-Or A., Cheung R., et al. Abnormal T-cell reactivities in childhood inflammatory demyelinating disease and type 1 diabetes. Ann Neurol 2008, 63(1):98-111.
26. O'Connor K.C., McLaughlin K.A., De Jager P.L., et al. Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nat Med 2007, 13(2):211-217.
27. McLaughlin K.A., Chitnis T., Newcombe J., et al. Age-dependent B cell autoimmunity to a myelin surface antigen in pediatric multiple sclerosis. J Immunol 2009, 183(6):4067-4076.
28. O'Connor K.C., Lopez-Amaya C., Gagne D., et al. Anti-myelin antibodies modulate clinical expression of childhood multiple sclerosis. J Neuroimmunol 2010, 223(1/2):92-99.
29. Rostasy K., Withut E., Pohl D., et al. Tau, phospho-tau, and S-100B in the cerebrospinal fluid of children with multiple sclerosis. J Child Neurol 2005, 20(10):822-825.
30. Alotaibi S., Kennedy J., Tellier R., et al. Epstein-Barr virus in pediatric multiple sclerosis. JAMA 2004, 291(15):1875-1879.
31. Pohl D., Krone B., Rostasy K., et al. High seroprevalence of Epstein-Barr virus in children with multiple sclerosis. Neurology 2006, 67(11):2063-2065.
32. Lunemann J.D., Huppke P., Roberts S., et al. Broadened and elevated humoral immune response to EBNA1 in pediatric multiple sclerosis. Neurology 2008, 71(13):1033-1035.
33. Waubant EM, Mowry EM, Krupp LB, et al. Infections with CMV and, in those HLA-DRB1*15 positive, HSV-1, are associated with a lower risk of MS. Neurology, in press.
34. Mikaeloff Y., Caridade G., Tardieu M., et al. Parental smoking at home and the risk of childhood-onset multiple sclerosis in children. Brain 2007, 130(Pt 10):2589-2595.
35. Mowry E.M., Krupp L.B., Milazzo M., et al. Vitamin D status is associated with relapse rate in pediatric-onset multiple sclerosis. Ann Neurol 2010, 67(5):618-624.
36. Boiko A.N., Gusev E.I., Alekseenkov A.D., et al. Association and linkage of juvenile MS with HLA-DR2(15) in Russians. Neurology 2002, 58(4):658-660.
37. Hahn J.S., Pohl D., Rensel M., et al. Differential diagnosis and evaluation in pediatric multiple sclerosis. Neurology 2007, 68(16 Suppl 2):S13-S22.
38. Pohl D., Rostasy K., Treiber-Held S., et al. Pediatric multiple sclerosis: detection of clinically silent lesions by multimodal evoked potentials. J Pediatr 2006, 149(1):125-127.
39. Yeh E.A., Weinstock-Guttman B., Ramanathan M., et al. Magnetic resonance imaging characteristics of children and adults with paediatric-onset multiple sclerosis. Brain 2009, 132:3392-3400.
40. Dale R.C., de Sousa C., Chong W.K., et al. Acute disseminated encephalomyelitis, multiphasic disseminated encephalomyelitis and multiple sclerosis in children. Brain 2000, 123(Pt 12):2407-2422.
41. Tenembaum S., Chamoles N., Fejerman N. Acute disseminated encephalomyelitis: a long-term follow-up study of 84 pediatric patients. Neurology 2002, 59(8):1224-1231.
42. Banwell B., Ghezzi A., Bar-Or A., et al. Multiple sclerosis in children: clinical diagnosis, therapeutic strategies, and future directions. Lancet Neurol 2007, 6(10):887-902.
43. Chabas D., Castillo-Trivino T., Mowry E.M., et al. Vanishing MS T2-bright lesions before puberty: a distinct MRI phenotype?. Neurology 2008, 71(14):1090-1093.
44. Atzori M., Battistella P.A., Perini P., et al. Clinical and diagnostic aspects of multiple sclerosis and acute monophasic encephalomyelitis in pediatric patients: a single centre prospective study. Mult Scler 2009, 15(3):363-370.
45. Stark W., Huppke P., Gärtner J. Paediatric multiple sclerosis: the experience of the German Centre for Multiple Sclerosis in Childhood and Adolescence. J Neurol 2008, 255(Suppl 6):119-122.
46. Sindern E., Haas J., Stark E., et al. Early onset MS under the age of 16: clinical and paraclinical features. Acta Neurol Scand 1992, 86(3):280-284.
47. Ghezzi A., Pozzilli C., Liguori M., et al. Prospective study of multiple sclerosis with early onset. Mult Scler 2002, 8(2):115-118.
48. Gorman M.P., Healy B.C., Polgar-Turcsanyi M., et al. Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis. Arch Neurol 2009, 66(1):54-59.
49. Ruggieri M., Iannetti P., Polizzi A., et al. Multiple sclerosis in children under 10 years of age. Neurol Sci 2004, 25(Suppl 4):S326-S335.
50. Simone I.L., Carrara D., Tortorella C., et al. Course and prognosis in early-onset MS: comparison with adult-onset forms. Neurology 2002, 59(12):1922-1928.
51. Boyd J.R., MacMillan L.J. Multiple sclerosis in childhood: understanding and caring for children with an " adult" disease. Axone 2000, 22(2):15-21.
52. Amato M.P., Goretti B., Ghezzi A., et al. Cognitive and psychosocial features of childhood and juvenile MS. Neurology 2008, 70(20):1891-1897.
53. Thannhauser J.E. Grief-peer dynamics: understanding experiences with pediatric multiple sclerosis. Qual Health Res 2009, 19(6):766-777.
54. Thannhauser J.E., Mah J.K., Metz L.M. Adherence of adolescents to multiple sclerosis disease-modifying therapy. Pediatr Neurol 2009, 41(2):119-123.
55. Kaufman J., Birmaher B., Brent D., et al. Schedule for Affective Disorders and Schizophrenia for Schoo-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 1997, 36(7):980-988.
56. Weisbrot D.M., Ettinger A.B., Gadow K.D., et al. Psychiatric comorbidity in pediatric patients with demyelinating disorders. J Child Neurol 2010, 25(2):192-202.
57. Varni J.W., Burwinkle T.M., Szer I.S. The PedsQL Multidimensional Fatigue Scale in pediatric rheumatology: reliability and validity. J Rheumatol 2004, 31(12):2494-2500.
58. MacAllister W.S., Christodoulou C., Troxell R., et al. Fatigue and quality of life in pediatric multiple sclerosis. Mult Scler 2009, 15(12):1502-1508.
59. Banwell B.L., Anderson P.E. The cognitive burden of multiple sclerosis in children. Neurology 2005, 64(5):891-894.
60. MacAllister W.S., Belman A.L., Milazzo M., et al. Cognitive functioning in children and adolescents with multiple sclerosis. Neurology 2005, 64(8):1422-1425.
61. Bobholz J.A., Rao S.M. Cognitive dysfunction in multiple sclerosis: a review of recent developments. Curr Opin Neurol 2003, 16(3):283-288.
62. MacAllister W.S., Christodoulou C., Milazzo M., et al. Longitudinal neuropsychological assessment in pediatric multiple sclerosis. Dev Neuropsychol 2007, 32(2):625-644.
63. Amato M., Goretti B., Ghezzi A., et al. Cognitive and psychosocial features of childhood and juvenile multiple sclerosis: a reappraisal after 2 years. Neurology 2010, 75(13):1134-1140.
64. Till C., Broche B., Ghassemi R., et al. Corpus callosum area and thalamic volume as predictors of cognitive impairment in children and adolescents with MS. Neurology 2010, 74(Suppl 2):A507.
65. Benedict R.H., Ramasamy D., Munschauer F., et al. Memory impairment in multiple sclerosis: correlation with deep grey matter and mesial temporal atrophy. J Neurol Neurosurg Psychiatry 2009, 80(2):201-206.
66. Edwards S.G., Liu C., Blumhardt L.D. Cognitive correlates of supratentorial atrophy on MRI in multiple sclerosis. Acta Neurol Scand 2001, 104(4):214-223.
67. Ozturk A., Smith S.A., Gordon-Lipkin E.M., et al. MRI of the corpus callosum in multiple sclerosis: association with disability. Mult Scler 2010, 16(2):166-177.
68. Pohl D., Rostasy K., Reiber H., et al. CSF characteristics in early-onset multiple sclerosis. Neurology 2004, 63(10):1966-1967.
69. Chabas D., Castillo-Trivino T., Mowry E.M., et al. Vanishing MS T2-bright lesions before puberty: a distinct MRI phenotype?. Neurology 2008, 71(14):1090-1093.
70. Hynson J.L., Kornberg A.J., Coleman L.T., et al. Clinical and neuroradiologic features of acute disseminated encephalomyelitis in children. Neurology 2001, 56(10):1308-1312.
71. Mikaeloff Y., Suissa S., Vallée L., et al. First episode of acute CNS inflammatory demyelination in childhood: prognostic factors for multiple sclerosis and disability. J Pediatr 2004, 144(2):246-252.
72. Frohman E., Costello F., Zivadinov R., et al. Optical coherence tomography in multiple sclerosis. Lancet Neurol 2006, 5(10):853-863.
73. Mikaeloff Y., Adamsbaum C., Husson B., et al. MRI prognostic factors for relapse after acute CNS inflammatory demyelination in childhood. Brain 2004, 127(Pt 9):1942-1947.
74. Callen D.J., Shroff M.M., Branson H.M., et al. Role of MRI in the differentiation of ADEM from MS in children. Neurology 2009, 72(11):968-973.
75. Neuteboom R.F., Boon M., Catsman Berrevoets C.E., et al. Prognostic factors after a first attack of inflammatory CNS demyelination in children. Neurology 2008, 71(13):967-973.
76. Chitnis T., Pirko I. Sensitivity vs specificity: progress and pitfalls in defining MRI criteria for pediatric MS. Neurology 2009, 72(11):952-953.
77. Giovannoni G., Comi G., Cook S., et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med 2010, 362(5):416-426.
78. Comi G., O'Connor P., Montalban X., et al. Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results. Mult Scler 2010, 16(2):197-207.
79. Pliskin N.H., Hamer D.P., Goldstein D.S., et al. Improved delayed visual reproduction test performance in multiple sclerosis patients receiving interferon beta-1b. Neurology 1996, 47(6):1463-1468.
80. Weinstein A., Schwid S.R., Schiffer R.B., et al. Neuropsychologic status in multiple sclerosis after treatment with glatiramer. Arch Neurol 1999, 56(3):319-324.
81. Cohen J.A., Barkhof F., Comi G., et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010, 362(5):402-415.
82. Kappos L., Radue E.-M., O'Connor P., et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010, 362(5):387-401.
83. Mikaeloff Y., Moreau T., Debouverie M., et al. Interferon-beta treatment in patients with childhood-onset multiple sclerosis. J Pediatr 2001, 139(3):443-446.
84. Banwell B., Reder A.T., Krupp L., et al. Safety and tolerability of interferon beta-1b in pediatric multiple sclerosis. Neurology 2006, 66(4):472-476.
85. Bykova O.V., Kuzenkova L.M., Maslova O.I. [The use of beta-interferon-1b in children and adolescents with multiple sclerosis]. Zh Nevrol Psikhiatr Im S S Korsakova 2006, 106(9):29-33. [in Russian].
86. Tenembaum S.N., Segura M.J. Interferon beta-1a treatment in childhood and juvenile-onset multiple sclerosis. Neurology 2006, 67(3):511-513.
87. Pohl D., Rostasy K., Gärtner J., et al. Treatment of early onset multiple sclerosis with subcutaneous interferon beta-1a. Neurology 2005, 64(5):888-890.
88. Ghezzi A., Amato M.P., Capobianco M., et al. Treatment of early-onset multiple sclerosis with intramuscular interferonbeta-1a: long-term results. Neurol Sci 2007, 28(3):127-132.
89. Ghezzi A. Immunomodulatory treatment of early onset multiple sclerosis: results of an Italian Co-operative Study. Neurol Sci 2005, 26(Suppl 4):S183-S186.
90. Mikaeloff Y., Caridade G., Tardieu M., et al. Effectiveness of early beta interferon on the first attack after confirmed multiple sclerosis: a comparative cohort study. Eur J Paediatr Neurol 2008, 12(3):205-209.
91. Kornek B., Bernert G., Balassy C., et al. Glatiramer acetate treatment in patients with childhood and juvenile onset multiple sclerosis. Neuropediatrics 2003, 34(3):120-126.
92. Ghezzi A., Amato M.P., Capobianco M., et al. Disease-modifying drugs in childhood-juvenile multiple sclerosis: results of an Italian Co-operative Study. Mult Scler 2005, 11(4):420-424.
93. Huppke P., Stark W., Zürcher C., et al. Natalizumab use in pediatric multiple sclerosis. Arch Neurol 2008, 65(12):1655-1658.
94. Ghezzi A., Pozzilli C., Grimaldi L.M., et al. Safety and efficacy of natalizumab in children with multiple sclerosis. Neurology 2010, 75(10):912-917.
95. Yeh E, Krupp L, Ness J, et al. Breakthrough disease in pediatric MS patients: a pediatric network experience. Annual Meeting of the American Academy of Neurology. Seattle (WA), May 1, 2009.
96. Karenfort M., Kieseier B.C., Tibussek D., et al. Rituximab as a highly effective treatment in a female adolescent with severe multiple sclerosis. Dev Med Child Neurol 2009, 51(2):159-161.
97. Makhani N., Gorman M.P., Branson H.M., et al. Cyclophosphamide therapy in pediatric multiple sclerosis. Neurology 2009, 72(24):2076-2082.
98. Kuntz N.L., Chabas D., Weinstock-Guttman B., et al. Treatment of multiple sclerosis in children and adolescents. Expert Opin Pharmacother 2010, 11(4):505-520.
99. Lukban M.B., Rosales R.L., Dressler D. Effectiveness of botulinum toxin A for upper and lower limb spasticity in children with cerebral palsy: a summary of evidence. J Neural Transm 2009, 116(3):319-331.
100. Gooch J.L., Patton C.P. Combining botulinum toxin and phenol to manage spasticity in children. Arch Phys Med Rehabil 2004, 85(7):1121-1124.
101. Beers S.R., Skold A., Dixon C.E., et al. Neurobehavioral effects of amantadine after pediatric traumatic brain injury: a preliminary report. J Head Trauma Rehabil 2005, 20(5):450-463.
102. Hurst D.L., Lajara-Nanson W. Use of modafinil in spastic cerebral palsy. J Child Neurol 2002, 17(3):169-172.
103. Stankoff B., Waubant E., Confavreux C., et al. Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study. Neurology 2005, 64(7):1139-1143.
104. Wingerchuk D.M., Benarroch E.E., O'Brien P.C., et al. A randomized controlled crossover trial of aspirin for fatigue in multiple sclerosis. Neurology 2005, 64(7):1267-1269.
105. Schwid S.R., Petrie M.D., McDermott M.P., et al. Quantitative assessment of sustained-release 4-aminopyridine for symptomatic treatment of multiple sclerosis. Neurology 1997, 48(4):817-821.
106. Bever C.T., Judge S.I. Sustained-release fampridine for multiple sclerosis. Expert Opin Investig Drugs 2009, 18(7):1013-1024.
107. Goodman A.D., Brown T.R., Krupp L.B., et al. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet 2009, 373(9665):732-738.
108. Kachuck N.J. Sustained release oral fampridine in the treatment of multiple sclerosis. Expert Opin Pharmacother 2009, 10(12):2025-2035.
109. Geny C., Nguyen J.P., Pollin B., et al. Improvement of severe postural cerebellar tremor in multiple sclerosis by chronic thalamic stimulation. Mov Disord 1996, 11(5):489-494.
110. Schulder M., Sernas T.J., Karimi R. Thalamic stimulation in patients with multiple sclerosis: long-term follow-up. Stereotact Funct Neurosurg 2003, 80(1-4):48-55.
111. Kilic N., Balkan E., Akgoz S., et al. Comparison of the effectiveness and side-effects of tolterodine and oxybutynin in children with detrusor instability. Int J Urol 2006, 13(2):105-108.
112. Rodriguez M., Warrington A.E., Pease L.R. Invited article: human natural autoantibodies in the treatment of neurologic disease. Neurology 2009, 72(14):1269-1276.
113. Sim F.J., Zhao C., Penderis J., et al. The age-related decrease in CNS remyelination efficiency is attributable to an impairment of both oligodendrocyte progenitor recruitment and differentiation. J Neurosci 2002, 22(7):2451-2459.
114. Zhao C., Li W.W., Franklin R.J. Differences in the early inflammatory responses to toxin-induced demyelination are associated with the age-related decline in CNS remyelination. Neurobiol Aging 2006, 27(9):1298-1307.
115. Mina R., Brunner H.I. Pediatric lupus-are there differences in presentation, genetics, response to therapy, and damage accrual compared with adult lupus?. Rheum Dis Clin North Am 2010, 36(1):53-80. vii-viii.
116. Baumann R.J., Robertson W.C. Neurosarcoid presents differently in children than in adults. Pediatrics 2003, 112(6 Pt 1):e480-e486.
117. Duzova A., Bakkaloglu A. Central nervous system involvement in pediatric rheumatic diseases: current concepts in treatment. Curr Pharm Des 2008, 14(13):1295-1301.
118. Goo H.W., Weon Y.C. A spectrum of neuroradiological findings in children with haemophagocytic lymphohistiocytosis. Pediatr Radiol 2007, 37(11):1110-1117.
119. Marais B.J., Gie R.P., Schaaf H.S., et al. The spectrum of disease in children treated for tuberculosis in a highly endemic area. Int J Tuberc Lung Dis 2006, 10(7):732-738.
120. Van Rie A., Harrington P.R., Dow A., et al. Neurologic and neurodevelopmental manifestations of pediatric HIV/AIDS: a global perspective. Eur J Paediatr Neurol 2007, 11(1):1-9.
121. Kastrup O., Wanke I., Maschke M. Neuroimaging of infections of the central nervous system. Semin Neurol 2008, 28(4):511-522.
122. Shah I., Chudgar P. Progressive multifocal leukoencephalopathy (PML) presenting as intractable dystonia in an HIV-infected child. J Trop Pediatr 2005, 51(6):380-382.
123. Mygland A., Ljostad U., Fingerle V., et al. EFNS guidelines on the diagnosis and management of European Lyme neuroborreliosis. Eur J Neurol 2010, 17(1):8-16. e1-4.
124. Oschmann P., Dorndorf W., Hornig C., et al. Stages and syndromes of neuroborreliosis. J Neurol 1998, 245(5):262-272.
125. Fernandez R.E., Rothberg M., Ferencz G., et al. Lyme disease of the CNS: MR imaging findings in 14 cases. AJNR Am J Neuroradiol 1990, 11(3):479-481.
126. Bitnun A., Ford-Jones E., Blaser S., et al. Mycoplasma pneumoniae ecephalitis. Semin Pediatr Infect Dis 2003, 14(2):96-107.
127. Louis E.D., Lynch T., Kaufmann P., et al. Diagnostic guidelines in central nervous system Whipple's disease. Ann Neurol 1996, 40(4):561-568.
128. Chamberlain M.C., Glantz M., Groves M.D., et al. Diagnostic tools for neoplastic meningitis: detecting disease, identifying patient risk, and determining benefit of treatment. Semin Oncol 2009, 36(4 Suppl 2):S35-S45.
129. Chamberlain M.C., Johnston S.K., Van Horn A., et al. Recurrent lymphomatous meningitis treated with intra-CSF rituximab and liposomal ara-C. J Neurooncol 2009, 91(3):271-277.
130. Fattapposta F., Restuccia R., Pirro C., et al. Early diagnosis in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL): the role of MRI. Funct Neurol 2004, 19(4):239-242.
131. Callen D.J., Shroff M.M., Branson H.M., et al. MRI in the diagnosis of pediatric multiple sclerosis. Neurology 2009, 72(11):961-967.
132. Kaye E.M. Update on genetic disorders affecting white matter. Pediatr Neurol 2001, 24(1):11-24.
133. Sasaki M., Sakuragawa N., Takashima S., et al. MRI and CT findings in Krabbe disease. Pediatr Neurol 1991, 7(4):283-288.
134. Shapiro E.G., Lockman L.A., Knopman D., et al. Characteristics of the dementia in late-onset metachromatic leukodystrophy. Neurology 1994, 44(4):662-665.
135. van der Knaap M.S., Kamphorst W., Barth P.G., et al. Phenotypic variation in leukoencephalopathy with vanishing white matter. Neurology 1998, 51(2):540-547.
136. Pridmore C.L., Baraitser M., Harding B., et al. Alexander's disease: clues to diagnosis. J Child Neurol 1993, 8(2):134-144.
137. Wallace D.C. Mitochondrial diseases in man and mouse. Science 1999, 283(5407):1482-1488.
138. Kalb R.C., DiLorenzo T.A., La Rocca N.G., et al. The impact of early-onset multiple sclerosis on cognitive and psychosocial indices. International Journal of MS Care 1999, 1(1):2-17.
139. Weisbrot D.M., Ettinger A.B., Gadow K.D., et al. Psychiatric comorbidity in pediatric patients with demyelinating disorders. J Child Neurol 2010, 25(2):192-202.
140. MacAllister W.S., Krupp L.B., Christodoulou C., et al. Progressive cognitive decline in pediatric MS. Neurology 2005, 64(6):A322.